This international, randomized, double-blind trial (NCT01864174) compared the efficacy and safety of metformin extended-release (XR) and immediate-release (IR) in patients with type 2 diabetes. After a 4-week placebo lead-in, pharmacotherapy-naïve adults with glycated haemoglobin (HbA1c) at 7.0% to 9.2% were randomized (1:1) to receive once-daily metformin XR 2000 mg or twice-daily metformin IR 1000 mg for 24 weeks. The primary endpoint was change in HbA1c after 24 weeks. Secondary endpoints were change in fasting plasma glucose (FPG), mean daily glucose (MDG) and patients (%) with HbA1c <7.0% after 24 weeks. Overall, 
| INTRODUCTION
Metformin, a first-line treatment for patients with type 2 diabetes, is available as an immediate-release (IR) formulation, typically administered several times daily with meals, and an extended-release (XR) formulation, administered once daily. [1] [2] [3] [4] [5] [6] The pharmacokinetic properties of metformin IR are generally comparable to those of the XR formulation. 7 However, peak plasma concentrations (C max ) for metformin IR occur~3 hours after a single oral 1000-mg dose (mean C max [standard deviation (SD)], 1321 [234] ng/mL), whereas peak plasma concentrations of metformin XR 2000 mg occur within 7 to 8 hours after dosing (mean C max [SD] , 1780 [288] ng/mL). 7 Both formulations are well tolerated and are effective in reducing glycated haemoglobin (HbA1c) levels as compared to placebo in patients with type 2 diabetes. 8, 9 Previous studies have shown greater patient adherence 10, 11 and indicate improved gastrointestinal (GI) tolerability with metformin XR compared with metformin IR. [11] [12] [13] Despite widespread use of both metformin IR and XR preparations, only 2 head-to-head clinical trials comparing the safety and efficacy of metformin IR and metformin XR have been conducted, one in the USA and the other in China. 11, 12 However, both studies included patients who had previously received metformin. 11, 12 The
Chinese study had an open-label design, comprising a relatively small number of patients and comparing the 2 metformin formulations at 1500 mg/d over 12 weeks. 11 The US study was larger and of a longer duration than the Chinese study and compared metformin XR (at different dosages) with metformin IR at a dose of 1500 mg/d. In the US study, patients previously treated with metformin and a sulphonylurea were permitted. 12 The aim of this trial was to evaluate the efficacy, safety and tolerability of the same 2000 mg daily doses of once-daily metformin XR versus twice-daily metformin IR in pharmacotherapy-naïve patients with type 2 diabetes.
2 | METHODS <250 mg/dL (13.9 mmol/L); C-peptide ≥1.0 ng/mL at enrolment. Key exclusion criteria were: history of ketoacidosis, lactic acidosis or hyperosmolar non-ketotic coma; marked polyuria; polydipsia with >10% weight loss during last 3 months prior to screening/enrolment; and elevated serum creatinine levels. Patients provided written informed consent before participating in the study, which followed the ethical principles of the Declaration of Helsinki.
| Study design

| Study assessments
The primary efficacy endpoint was mean change in HbA1c from baseline to week 24, which was also examined by baseline HbA1c subgroup (<8%, ≥8 to <9% and ≥9%). 
| Statistical analyses
Given a sample size of 235 patients/group, the study would provide 90% power to demonstrate non-inferiority in change from baseline to week 24 in mean HbA1c (assumed SD, 1.0%; non-inferiority margin, 0.3%; 2-sided α = 0.05). Assuming that approximately 10% of patients would not have a post-baseline value, approximately 524 patients would be required for randomization.
The primary efficacy endpoint was analysed using a longitudinal repeated-measures model, which adjusted for baseline HbA1c, treatment group, time, baseline-by-time interaction and time-by-treatment group interaction. Changes in FPG were assessed using the same model. For MDG, changes from baseline to week 24/LOCF were analysed using an analysis of covariance (ANCOVA) model. For the percentage of patients with HbA1c <7.0% at week 24, data were analysed using logistic regression, 14, 15 with adjustments for baseline HbA1c. These analyses were performed using data from patients who received at least 1 dose of double-blind study drug during the randomized treatment period (randomized data set). Values prior to initiation of rescue medication were used for analysis of these data.
The treated data set includes all patients who received at least 1 dose of double-blind study drug during the treatment period, regardless of rescue.
3 | RESULTS
| Patient disposition and baseline characteristics
Of the 1736 patients enroled, 794 (45.7%) were eligible to enter the placebo lead-in period, of whom 568 patients were randomized (1:1)
to receive either once-daily metformin XR (N = 283) or twice-daily metformin IR (N = 285) ( Figure S1 ). The most common reason for study non-eligibility or non-randomization was no longer meeting study criteria ( Figure S1 ). Of those patients who were randomized, 29 were excluded because of study site non-compliance. Thus, the randomized data set became metformin XR (N = 268) and metformin IR (N = 271). Overall, 245 patients in both groups completed the double-blind period of the study. Baseline demographics and disease characteristics are shown in Table S1 .
| Extent of exposure
Patients receiving once-daily metformin XR and twice-daily metformin IR had similar exposure and total daily doses of study drug (Table S2) . Down-titration because of metformin intolerance was implemented in 37 and 108 patients receiving metformin XR and IR, respectively. However, for patients who were down-titrated, up-titrations/rechallenges with higher doses were attempted before week 12. Eight patients received rescue medication (metformin XR, n = 3; metformin IR, n = 5) (Table S2 ).
| Efficacy
Baseline mean (standard deviation) HbA1c was 7.58% (0. (Table S3) . Baseline adjusted changes in mean (SE) FPG and MDG levels, and percentage of patients with HbA1c <7.0% at week 24/LOCF were similar between treatment arms (Table 1) , as were changes in body weight, waist circumference and serum lipid profiles (Table S4 ).
| Safety and tolerability
Overall, 50.2% (142/283) and 47.4% (135/285) of patients in the metformin XR and IR groups reported at least 1 treatment-emergent AE, respectively (Table S5 ). Of these, 10.6% and 8.8% were considered treatment-related, respectively. Serious AEs (SAEs) were reported for 2.8% (8/283) and 3.5% (10/285) of patients receiving metformin XR and IR, respectively; only 1 case per group was considered treatment-related. The most common reason for discontinuation because of AEs was GI disorders (metformin XR, 1.4%; metformin IR, 1.4%). The most frequently reported AEs were GI in nature, ie, diarrhoea, nausea and vomiting (Table S5 ). There were no clinically meaningful changes in vital signs or standard laboratory variables, including creatinine, hepatic panel and urinalysis parameters.
| Hypoglycaemia
After 24 weeks of treatment, no hypoglycaemia events were reported in patients receiving once-daily metformin XR compared with 3 patients (1.1%) receiving twice-daily metformin IR. There were 5 events in total: 2 classified as "probable symptomatic hypoglycaemia" and 3 as "relative hypoglycaemia" (according to American Diabetes Association recommendations). Once-daily metformin XR and twice-daily metformin IR were well tolerated, as reported in the literature 11, 12 and product labelling. Notably, the most common AE was diarrhoea in both treatment groups. The frequency of nausea was slightly higher with metformin XR than with metformin IR (4.6% vs 2.8%, respectively), which contrasts with the previous head-to-head trials 11, 12 ; however, overall, nausea was reported by few patients in both groups. Moreover, AEs and SAEs leading to study discontinuation were reported for fewer than 5% of patients in both treatment groups.
| DISCUSSION
In this study, down-titration because of metformin intolerance (a large proportion of patients did not meet the study criteria) and were motivated to comply with medication; however, outside of a controlled study setting, the potential patient compliance benefits of once-daily vs twice-daily dosing are more likely to become apparent.
In conclusion, this international head-to-head trial has demonstrated the therapeutic equivalence of metformin XR and metformin IR over a 24-week period in pharmacotherapy-naïve patients with type 2 diabetes, and confirms metformin XR as an important treatment option for patients in whom dosing frequency could affect medication compliance and compromise treatment outcomes. and interpretation of the data. All authors have made a substantial contribution to drafting the article or reviewing it critically. All authors have given final approval of this version of the article to be published.
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